Vir Biotechnology Q4 revenue beats estimates

Reuters

02/24

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Q4 revenue beats estimates

Overview

Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue
Company reported a net loss for Q4, decreased compared to last year
Company announced collaboration with Astellas for prostate cancer treatment development

Outlook

Vir expects cash reserves to fund operations into Q2 2028

Result Drivers

NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment
COST SAVINGS - Decrease in R&D and SG&A expenses due to cost savings from restructuring initiatives

Company press release: ID:nBwbtQvVSa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$64.10 mln	$23.18 mln (6 Analysts)
Q4 EPS		-$0.31
Q4 Net Income		-$42.9 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2613753694"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613753694\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613753694?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613753694","market":"nz","top_or_hot":-1,"title":"Vir Biotechnology Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue</p></li><li><p>Company reported a net loss for Q4, decreased compared to last year</p></li><li><p>Company announced collaboration with Astellas for prostate cancer treatment development</p></li></ul><p><span>Outlook</span></p><ul><li><p>Vir expects cash reserves to fund operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment</p></li><li><p>COST SAVINGS - Decrease in R&amp;D and SG&amp;A expenses due to cost savings from restructuring initiatives</p></li></ul><p>Company press release: <span>ID:nBwbtQvVSa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$64.10 mln</p></td><td><p>$23.18 mln (6 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.31</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$42.9 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Q4 revenue beats estimates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-24 06:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue</p></li><li><p>Company reported a net loss for Q4, decreased compared to last year</p></li><li><p>Company announced collaboration with Astellas for prostate cancer treatment development</p></li></ul><p><span>Outlook</span></p><ul><li><p>Vir expects cash reserves to fund operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment</p></li><li><p>COST SAVINGS - Decrease in R&amp;D and SG&amp;A expenses due to cost savings from restructuring initiatives</p></li></ul><p>Company press release: <span>ID:nBwbtQvVSa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$64.10 mln</p></td><td><p>$23.18 mln (6 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.31</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$42.9 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ159:1","article_id":"2613753694","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613753694","pubTimestamp":1771885387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Q4 revenue beats estimatesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenueCompany reported a net loss for Q4, decreased compar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc.","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4535":"淡马锡持仓"},"translate_title":"Vir Biotechnology第四季度收入超出预期","themeId":"820bd9599ffb63504ba3f82e9df01528","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Q4 revenue beats estimatesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenueCompany reported a net loss for Q4, decreased compared to last yearCompany announced collaboration with Astellas for prostate cancer treatment developmentOutlookVir expects cash reserves to fund operations into Q2 2028Result DriversNORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatmentCOST SAVINGS - Decrease in R&D and SG&A expenses due to cost savings from restructuring initiativesCompany press release: ID:nBwbtQvVSaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$64.10 mln$23.18 mln (6 Analysts)Q4 EPS-$0.31Q4 Net Income-$42.9 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}